ECU
EW icon

Eisler Capital (US)’s Edwards Lifesciences EW Stock Holding History

Eisler Capital (US)’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-55,857
Closed -$5.16M – 534
2024
Q2 		$5.16M Buy
+55,857
New +$4.95M 0.09% 193

Other funds holding EW

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Eisler Capital (US)'s EW Position: Q3 2024 in Review

Eisler Capital (US) sold out of Edwards Lifesciences (EW) in Q3 2024, closing a stake of 55,857 shares — an estimated $5.16M sold.

Eisler Capital (US) first reported a position in EW in Q2 2024 and held it in 1 quarter. The position peaked at $5.16M in Q2 2024. 1,194 funds tracked by Wall St. Rank hold EW as of Q3 2024.

  • Eisler Capital (US) reported no remaining Edwards Lifesciences position as of Q3 2024 after selling out during the quarter.
  • Eisler Capital (US) sold 55,857 Edwards Lifesciences shares in Q3 2024, an estimated $5.16M.
  • Eisler Capital (US) first reported a position in Edwards Lifesciences in Q2 2024 and held it in 1 quarter.
  • Eisler Capital (US)'s Edwards Lifesciences position peaked at $5.16M in Q2 2024.
  • 1,194 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q3 2024.

Based on Eisler Capital (US)'s 13F filing for Q3 2024, filed 14 Nov 2024.